Evidence map›Paper›PMID 39533519›Full record

Trial reportClinical and translational science2024

Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.

Pavan Vaddady, Giovanni Smania, Shintaro Nakayama, Hiroyuki Inoue, Abhinav Kurumaddali, Malaz Abutarif, Ming Zheng

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pavan VaddadyQuantitative Clinical Pharmacology Department, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.ORCID 0000-0002-7369-6649
Giovanni SmaniaPharmetheus AB, Uppsala, Sweden.
Shintaro NakayamaQuantitative Clinical Pharmacology Department, Daiichi Sankyo Co, Ltd., Tokyo, Japan.
Hiroyuki InoueQuantitative Clinical Pharmacology Department, Daiichi Sankyo Co, Ltd., Tokyo, Japan.
Abhinav KurumaddaliQuantitative Clinical Pharmacology Department, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.ORCID 0000-0001-7489-5108
Malaz AbutarifQuantitative Clinical Pharmacology Department, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
Ming ZhengQuantitative Clinical Pharmacology Department, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quizartinib prolongs QT interval through inhibition of the slow delayed rectifier potassium current (I

Indexed as

Benzothiazolesfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcutePhenylurea CompoundsAdultAgedDose-Response Relationship, DrugElectrocardiographyFemaleGene DuplicationHumansMaleMiddle AgedYoung AdultBenzothiazolesFLT3 protein, humanfms-Like Tyrosine Kinase 3Phenylurea Compoundsquizartinib

Identifiers

PMID39533519
PMCPMC11557512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.